Meissa Vaccines, Inc.
JLABS, Oyster Point Boulevard, 3rd Floor
South San Francisco
About Meissa Vaccines, Inc.Meissa Vaccines is a start-up pharmaceutical development company focused on the in-licensing and advancement of vaccines for respiratory syncytial virus (RSV, the largest unmet respiratory medical need in pediatrics) and rhinovirus (leading cause of infectious disease worldwide).
Founder and CEO: Marty Moore
Fouinder and CSO: Roderick Tang
CMO: Marc Gurwith
CBO: Piers Whitehead
Please click here for clinical trial information.
18 articles with Meissa Vaccines, Inc.
Meissa’s intranasal vaccine for COVID-19 equals the protection afforded by existing vaccines in the same class of subjects after only a single dose, according to data presented this week at the American Society of Virology annual meeting.
Meissa Vaccines announced today the first seronegative participants have received MV-012-968, Meissa’s intranasal live attenuated RSV vaccine candidate, in a Phase 1c study in infants and young children.
Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants) recently was cleared for Phase I trials, which will start at the end of March.
Meissa Announces First Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV
The randomized, double-blind, placebo-controlled challenge study is designed to evaluate safety and prophylactic efficacy of MV-012-968 against symptomatic respiratory syncytial virus (RSV)
10/16/2020Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.
Meissa Vaccines Expands Leadership Team as Company Advances Intranasal RSV and COVID-19 Live Attenuated Vaccine Candidates
Vaccine manufacturing and regulatory expert and business development and strategy leader bring further expertise as company advances RSV vaccine candidate into Phase 2 and scales production of an intranasal COVID-19 vaccine candidate for clinical trials REDWOOD CITY, Calif.--( BUSINESS WIRE )-- Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today the appointments of William
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 20, 2020.
Another COVID-19 vaccine candidate recently entered the races. The difference – this one is a live attenuated (weakened) virus expressing the coronavirus’s signature spike protein on its surface. And it’s delivered nasally, not a shot.
Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands Preliminary clinical data show MV-012-968, the company’s vaccine candidate for respiratory syncytial virus, is heavily attenuated and induces a RSV-specific mucosal IgA response in the majority of healthy adult, seropositive recipients SOUTH SAN FRANCIS
6/26/2020Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.
Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the company has appointed Robert Jordan, Ph.D., Vice President, Research and Development. Dr. Jordan has more than 20 years of virology research and antiviral drug development experience in both academia and industry. He was most recently Director, Virology at Vir Biotechnolo
Meissa Vaccines Receives FDA Clearance of IND Application for a Phase 1 Clinical Trial of MV-012-968 for Respiratory Syncytial Virus
Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application to proceed with a U.S. clinical trial of MV-012-968, an investigational vaccine for respiratory syncytial virus (RSV).
Company uses proprietary synthetic biology and genetic engineering technologies to design improved vaccines for serious respiratory infections
The financing included numerous undisclosed individual investors and will be used to advance the company’s RSV vaccine candidate into clinical trials.
Meissa Vaccines, a biotechnology company developing vaccines to prevent viral respiratory infections, announced that Martin Moore, Ph.D., co-founder and CEO of Meissa Vaccines, will present at World Vaccine Congress Washington 2018.
Meissa Vaccines Awarded $1.6M Fast Track SBIR Grant To Advance IND Preparations For RSV Vaccine Candidate
Meissa Vaccines Announces Award Of NIH SBIR Grant To Support Development Of Multivalent Human Rhinovirus Vaccine Candidate